Therefore, it is controversial whether additional checkpoint therapies, targeting additional immune checkpoints, will confer clinical benefit to ccRCC patients with an immune profile composed of M2-like TAMs and terminally exhausted CD8+ T cell states. The gene discussed is CD8A; the disease is nonpapillary renal cell carcinoma.